07 — PIPELINE

眼科正在從「反覆打針」走向「一次處理」。

Ophthalmology is moving from repeat injections to one-time biology.

二十年來,濕性黃斑病變幾乎等於每隔一、兩個月回診打一針抗 VEGF——藥效停在你停止打針的那天。2025–2026 年的賭注是把這件事做一次:把基因、細胞、或可持續分泌保護因子的植入體留在眼球裡,讓它自己接著運作。

For twenty years, wet AMD has meant an anti-VEGF shot every month or two — a drug that works only while you keep getting it. The 2025–2026 bet is to do that job once: leave a gene, a graft of cells, or a factor-secreting implant in the eye so the biology keeps working without the waiting room.

同一種轉向,正在三個不同病種上同時發生。三條線同等重要——服務的是不同病人。接近診所的程度則不同。以下多數仍是試驗,不是診所菜單。

That same shift is being tried on three different diseases at once. The tracks are equally important — they serve different patients. They are not equally close to the clinic. Most of this is still a trial, not a menu.

FROM

反覆打針、長期管理

Repeat shots, chronic management

濕性黃斑:抗 VEGF 打好幾年。地圖狀萎縮:補體針只能減慢、不能補回。遺傳性視網膜病:一個基因一個藥,或沒藥。

Wet AMD: years of anti-VEGF. Geographic atrophy: complement shots that slow loss, not restore it. Inherited disease: one gene, one drug — or nothing.

TO

一次生物學處理

One-time biology

一次基因注射讓眼睛產藥。一次 RPE 移植或光伏晶片。一次不限突變的光遺傳或神經保護植入。三個病種,同一邏輯。

One gene shot that manufactures the drug. One RPE graft or photovoltaic chip. One mutation-agnostic optogenetic or neurotrophic implant. Three diseases, one logic.

ONE HEADLINE · THREE DISEASES

同一句話,三個病種,沒有主次

One headline. Three diseases. No ranking.

標題不是只講濕性黃斑。它是同一種賭注,用在三個不同問題上:有針可打的,換成一次基因;針打了也補不回的,換成一次細胞或晶片;基因太多打不完的,換成一次不限突變的處理。點一張卡看機制與論文;長條是接近診所的程度,不是重要性。

The headline is not wet AMD alone. It is the same bet on three different problems: where shots already exist, replace the calendar with one gene; where shots cannot restore tissue, graft cells or place a chip once; where there are too many genes to treat one by one, do a mutation-agnostic procedure once. Pick a card for mechanism and papers. The bar is closeness to clinic, not importance.

HOW IT WORKS · WET AMD

把抗 VEGF 的基因送進視網膜細胞

Deliver an anti-VEGF gene into retinal cells

這是標題最直接的那一條:停掉打針月曆。一次玻璃體腔注射,目標是換掉往後數年的抗 VEGF。

This is the headline in its strictest form: stop the injection calendar. One intravitreal shot aims to replace years of anti-VEGF.

接近診所:高(第三期進行中,讀數約 2026–27)。長效 TKI(如 Axpaxli)是半途:針比較少,還不是一次處理。

Closeness to clinic: high (Phase 3 running; readouts ~2026–27). Long-acting TKIs such as Axpaxli are the halfway house: fewer shots, not yet one-time.

STEP 1工程病毒(AAV)載入抗 VEGF 或 aflibercept 基因。An AAV vector carries an anti-VEGF or aflibercept gene.
STEP 2注射入眼,細胞開始自己製造藥物。Injected into the eye; cells start making the drug.
STEP 34D-150 還多一條抑制 VEGF-C 的 RNA。4D-150 also encodes RNA against VEGF-C.
TIMELINE

點開節點看來源

Open a mark for sources

2025 AAO

酪胺酸激酶抑制劑與基因治療進入準上市討論。

TKIs and gene therapy treated as pre-launch.

2025 Oct–Nov

PRIMA 晶片 NEJM 發表;密歇根 RPE 幹細胞早期字母增加。

PRIMA in NEJM; Michigan RPE stem-cell letter gains.

2026 Q1

OCU410 第二期、Axpaxli SOL-1、角膜 CRISPR IND、OPGx-BEST1 首例。

OCU410 Phase 2, Axpaxli SOL-1, corneal CRISPR IND, first OPGx-BEST1 patient.

2026–2027

RGX-314、ixo-vec、4D-150 第三期陸續讀出。

RGX-314, ixo-vec and 4D-150 Phase 3 readouts.

PIPELINE

試驗卡

Trial cards

長效藥是半途:針比較少,還不是標題裡的一次處理。三條主線沒有主次;篩選只是方便對照試驗。Long-acting drugs are the halfway house: fewer shots, not the headline’s one-time act. The three tracks are not ranked; filters are only for comparing trials.

PHASE 3

4D-150

一次注射產 aflibercept + 抑制 VEGF-C。4FRONT 已入組。

One shot making aflibercept + VEGF-C knockdown. 4FRONT enrolled.

PHASE 3

RGX-314 / ixo-vec

AAV 編碼抗 VEGF 抗體或 aflibercept。預計最早讀出之一。

AAV encoding an anti-VEGF fragment or aflibercept. Among the earliest readouts.

NEJM 2025

PRIMA implant

38 人植入,12 個月 81% 中央視力有臨床意義改善。

38 implanted; 81% had a clinically meaningful central-vision gain at 12 months.

PHASE 1–2

RPE cells / OCU410

幹細胞 RPE 移植;OCU410 用 RORA 基因減慢地圖狀萎縮生長。

Stem-cell RPE grafts; OCU410 uses RORA to slow GA growth.

FDA

Encelto

CNTF 細胞植入,目前唯一獲批的 MacTel 2 治療。

CNTF cell implant; currently the only approved MacTel 2 therapy.

PHASE 3

Axpaxli (OTX-TKI)

axitinib 水凝膠。SOL-1:36 周維持視力優於 2 mg aflibercept。

Axitinib hydrogel. SOL-1: vision maintenance at week 36 beat 2 mg aflibercept.

來源:NEJM、ClinicalTrials.gov、Ophthalmology Times、ScienceDaily、FDA、AJMC。試驗結果會改寫結論;本頁不是用藥依據。

Sources: NEJM, ClinicalTrials.gov, Ophthalmology Times, ScienceDaily, FDA, AJMC. Readouts will rewrite this. Not prescribing information.